Endo International PLC (NASDAQ:ENDP) (TSE:ENL) – Equities research analysts at Oppenheimer Holdings increased their FY2017 earnings per share (EPS) estimates for Endo International PLC in a research report issued to clients and investors on Monday. Oppenheimer Holdings analyst D. Archila now forecasts that the company will earn $3.56 per share for the year, up from their prior forecast of $3.52. Oppenheimer Holdings currently has a “Hold” rating on the stock. Oppenheimer Holdings also issued estimates for Endo International PLC’s Q1 2018 earnings at $0.66 EPS, Q2 2018 earnings at $0.66 EPS, FY2020 earnings at $3.68 EPS and FY2021 earnings at $3.91 EPS.
ENDP has been the subject of several other reports. William Blair reissued a “market perform” rating on shares of Endo International PLC in a research report on Wednesday, June 14th. Royal Bank Of Canada reissued a “sector perform” rating and issued a $9.00 price target (down from $15.00) on shares of Endo International PLC in a research report on Wednesday, August 9th. Morgan Stanley reduced their price target on Endo International PLC from $12.00 to $8.00 and set an “equal weight” rating for the company in a research report on Thursday, August 10th. Deutsche Bank AG set a $13.00 price target on Endo International PLC and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Finally, Canaccord Genuity set a $10.00 price target on Endo International PLC and gave the stock a “hold” rating in a research report on Monday, August 14th. Three investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and five have issued a buy rating to the stock. Endo International PLC presently has a consensus rating of “Hold” and an average target price of $12.80.
TRADEMARK VIOLATION WARNING: “Research Analysts Issue Forecasts for Endo International PLC’s FY2017 Earnings (ENDP)” was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://stocknewstimes.com/2017/10/11/research-analysts-issue-forecasts-for-endo-international-plcs-fy2017-earnings-endp.html.
Endo International PLC (NASDAQ:ENDP) opened at 8.60 on Wednesday. Endo International PLC has a 12-month low of $7.41 and a 12-month high of $21.87. The company’s market cap is $1.92 billion. The firm has a 50-day moving average price of $8.69 and a 200-day moving average price of $10.60.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last posted its quarterly earnings data on Tuesday, August 8th. The company reported $0.93 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.19. The business had revenue of $875.73 million during the quarter, compared to the consensus estimate of $832.66 million. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. The firm’s quarterly revenue was down 4.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.86 earnings per share.
Institutional investors and hedge funds have recently modified their holdings of the company. James Investment Research Inc. purchased a new stake in shares of Endo International PLC in the second quarter worth about $113,000. Blair William & Co. IL purchased a new stake in shares of Endo International PLC in the second quarter worth about $126,000. Point View Wealth Management Inc. boosted its stake in shares of Endo International PLC by 16.6% in the second quarter. Point View Wealth Management Inc. now owns 13,331 shares of the company’s stock worth $149,000 after buying an additional 1,900 shares during the last quarter. Riverhead Capital Management LLC boosted its stake in shares of Endo International PLC by 64.4% in the second quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock worth $168,000 after buying an additional 5,887 shares during the last quarter. Finally, Bank of Hawaii purchased a new stake in shares of Endo International PLC in the second quarter worth about $180,000. Hedge funds and other institutional investors own 90.71% of the company’s stock.
In related news, CEO Paul Campanelli bought 6,500 shares of the stock in a transaction dated Monday, August 14th. The shares were purchased at an average price of $7.71 per share, for a total transaction of $50,115.00. Following the completion of the purchase, the chief executive officer now directly owns 213,620 shares of the company’s stock, valued at $1,647,010.20. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Terrance J. Coughlin bought 20,000 shares of the stock in a transaction dated Thursday, August 10th. The stock was bought at an average price of $7.70 per share, for a total transaction of $154,000.00. Following the purchase, the chief operating officer now directly owns 181,369 shares of the company’s stock, valued at $1,396,541.30. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 36,000 shares of company stock worth $279,460. Company insiders own 0.50% of the company’s stock.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.